ATE317695T1 - Parenterale lösung enthaltend amiodaron - Google Patents

Parenterale lösung enthaltend amiodaron

Info

Publication number
ATE317695T1
ATE317695T1 AT01923027T AT01923027T ATE317695T1 AT E317695 T1 ATE317695 T1 AT E317695T1 AT 01923027 T AT01923027 T AT 01923027T AT 01923027 T AT01923027 T AT 01923027T AT E317695 T1 ATE317695 T1 AT E317695T1
Authority
AT
Austria
Prior art keywords
parenteral solution
amiodaron
solution containing
buffer
solution
Prior art date
Application number
AT01923027T
Other languages
English (en)
Inventor
James E Kipp
Mark J Doty
Christine L Rebbeck
Jan Y Eilert
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of ATE317695T1 publication Critical patent/ATE317695T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
AT01923027T 2000-03-30 2001-03-30 Parenterale lösung enthaltend amiodaron ATE317695T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/539,446 US6479541B1 (en) 2000-03-30 2000-03-30 Amiodarone-containing parenteral administration

Publications (1)

Publication Number Publication Date
ATE317695T1 true ATE317695T1 (de) 2006-03-15

Family

ID=24151243

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01923027T ATE317695T1 (de) 2000-03-30 2001-03-30 Parenterale lösung enthaltend amiodaron

Country Status (9)

Country Link
US (1) US6479541B1 (de)
EP (1) EP1267865B1 (de)
JP (2) JP4316834B2 (de)
AT (1) ATE317695T1 (de)
AU (2) AU4976601A (de)
CA (1) CA2404298A1 (de)
DE (1) DE60117248T2 (de)
MX (1) MXPA02009336A (de)
WO (1) WO2001074395A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479541B1 (en) * 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
US20020143051A1 (en) 2001-03-29 2002-10-03 Doty Mark J. Premixed amiodarone parenteral solution and method for making the same
EP1372637B1 (de) * 2001-03-29 2008-02-20 Baxter International Inc. Vorgemischte amiodaron-haltige parenterale lösung und deren herstellungsverfahren
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US7810124B2 (en) * 2003-01-28 2010-10-05 Thomson Licensing Robust mode staggercasting fast channel change
CA2559652C (en) * 2004-03-15 2017-02-14 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 in treating cancer
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2007258280B2 (en) 2006-06-12 2013-05-02 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
EP2335686A1 (de) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. Wässrige intravenöse Nanosuspension mit minimalen Nebenwirkungen
WO2011156481A2 (en) 2010-06-11 2011-12-15 Baxter International Inc. Formulations including amiodarone and salts thereof and methods of their manufacture and use
US9642828B2 (en) 2014-09-23 2017-05-09 Sun Pharmaceutical Industries Limited Parenteral dosage form of amiodarone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234949A (en) 1992-04-01 1993-08-10 Academic Pharmaceuticals, Inc. Parenteral solutions containing amiodarone in acetate buffer solution
FR2735978B1 (fr) * 1995-06-30 1997-09-19 Sanofi Sa Composition pharmaceutique d'amiodarone pour administration parenterale
US6030998A (en) 1997-06-27 2000-02-29 Academic Pharmaceuticals, Lp Methods for treating arrhythmia using acetate buffer solutions of amiodarone
US6479541B1 (en) * 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration

Also Published As

Publication number Publication date
US6479541B1 (en) 2002-11-12
EP1267865A2 (de) 2003-01-02
JP2003528929A (ja) 2003-09-30
DE60117248T2 (de) 2006-10-19
EP1267865B1 (de) 2006-02-15
CA2404298A1 (en) 2001-10-11
MXPA02009336A (es) 2003-01-28
JP2009114208A (ja) 2009-05-28
AU2001249766B2 (en) 2004-10-07
JP4316834B2 (ja) 2009-08-19
WO2001074395A3 (en) 2002-02-07
DE60117248D1 (de) 2006-04-20
AU4976601A (en) 2001-10-15
WO2001074395A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
DE60117248D1 (de) Parenterale lösung enthaltend amiodaron
YU23599A (sh) Stabilizovani antihistaminski sirup
BG107347A (bg) Висококонцентрирани стабилни разтвори на мелоксикам
CY1106206T1 (el) Φαρμακευτικη συνθεση πepιεχουσα φενοφιβρατη και μεθοδος παρασκευης της
BR9917007A (pt) Moduladores de ccr5
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
DK1056477T3 (da) Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
ATE429210T1 (de) Orale flüssige zusammensetzungen
CO5210911A1 (es) Trifluorbutenos nematicidas
DK1273299T3 (da) Minoxidilinindeholdende praparater
BR0208741A (pt) Derivados de piperidina
MA28038A1 (fr) Thienopyrazoles
BR0109598A (pt) Inibidores de quinase de proteìna tricìclicos
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
EA200200831A1 (ru) Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
UA42819C2 (uk) Ін`єкційний та інфузійний розчин, що містить енрофлокcацин
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
FR2775288B1 (fr) Derives de streptogramines, leur preparation et les compositons qui les contiennent
BR0104358A (pt) Formulações de taxana tendo solubilidade aperfeiçoada
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
CO4970704A1 (es) Solucion acuosa estable de em 12, y procedimiento de preparacion de dicha solucion
NO971604L (no) Orale sabeluzolsuspensjoner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties